Tag Archive for: cell and gene therapy

Astraveus Enters Strategic Partnership with NecstGen to evaluate Lakhesys Benchtop Cell FactoryTM for CAR-T therapy manufacturing

/in

Agreement with Netherlands Center for the Clinical Advancement of Stem Cell and Gene Therapies (NecstGen) for the manufacturing of CAR-T therapies using Lakhesys Benchtop Cell FactoryTM Partnership to demonstrate the ability of Astraveus’ technology to deliver reduced costs and increased efficiency in CAR-T manufacturing Paris, France, 6 May 2025 – Astraveus SAS (“Astraveus” or the […]

Read more

Hot topic: Should Pharma be looking east for new assets?

/in

“Go west, young man!”   Such was the famous advice of Horace Greeley, founder and editor of the (long defunct) New York Tribune, to an acquaintance, Josiah B. Grinnell, in the mid-19th century.  Countless individuals, businesses, and industries have since followed that advice – and gone on to strike gold.  But when it comes to where […]

Read more

Astraveus appoints Dr. Lars Henrik Peeck as Chief Business Development Officer

/in

Paris, France, 12 December 2023 – Astraveus SAS (“Astraveus” or the “Company”), the creator of the end-to-end benchtop cell factory to simplify cell and gene therapy (CGT) manufacturing, today announces the appointment of Dr. Lars Henrik Peeck as Chief Business Development Officer. Read more…

Read more

Highly experienced CDMO expert Michel Spagnol appointed Chairman of Astraveus

/in

Paris, France, 28 November, 2023 – Astraveus SAS (“Astraveus” or the “Company”), the creator of modular, microfluidic cell foundries that transform cell and gene therapy (CGT) manufacturing, today announces the appointment of Michel Spagnol as its new Chairman of the Board. Michel joins existing Board members Jérémie Laurent, CEO; Alain Huriez, Director; AdBio Partners; Christian […]

Read more

Leucid Bio Appoints Filippo Petti as Chief Executive Officer

/in

London, UK – 18 July 2023 – Leucid Bio (“Leucid” or the “Company”), a biotech company pursuing a differentiated approach to develop next generation Chimeric Antigen Receptor T-cell (CAR-T) therapies using the Company’s proprietary Lateral CAR platform, today announced the appointment of Filippo Petti as its Chief Executive Officer, with immediate effect. Mr. Petti has […]

Read more